Pulse Biosciences公布Npulse™ Vybrance™系统首次人体临床试验中良性甲状腺结节消融的持久性数据

美股速递03-09

Pulse Biosciences公司近日宣布，其Npulse™ Vybrance™系统在针对良性甲状腺结节消融的首次人体临床耐久性研究中取得了积极数据。该研究旨在评估该技术在治疗良性甲状腺结节方面的长期效果与安全性。

研究结果显示，Npulse™ Vybrance™系统在消融良性甲状腺结节方面展现出显著的持久性，为患者提供了一种潜在的非侵入性治疗选择。这一进展标志着公司在医疗技术领域的创新突破，有望为甲状腺疾病治疗带来新的解决方案。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1199241533?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-09 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199241533","market":"us","top_or_hot":-1,"title":"Pulse Biosciences公布Npulse™ Vybrance™系统首次人体临床试验中良性甲状腺结节消融的持久性数据","media":"美股速递","content":"<p>Pulse Biosciences公司近日宣布，其Npulse™ Vybrance™系统在针对良性甲状腺结节消融的首次人体临床耐久性研究中取得了积极数据。该研究旨在评估该技术在治疗良性甲状腺结节方面的长期效果与安全性。</p>\n<p>研究结果显示，Npulse™ Vybrance™系统在消融良性甲状腺结节方面展现出显著的持久性，为患者提供了一种潜在的非侵入性治疗选择。这一进展标志着公司在医疗技术领域的创新突破，有望为甲状腺疾病治疗带来新的解决方案。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pulse Biosciences公布Npulse™ Vybrance™系统首次人体临床试验中良性甲状腺结节消融的持久性数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPulse Biosciences公布Npulse™ Vybrance™系统首次人体临床试验中良性甲状腺结节消融的持久性数据\n</h2>\n\n<h4 class=\"meta\">\n\n2026-03-09 19:02 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pulse Biosciences公司近日宣布，其Npulse™ Vybrance™系统在针对良性甲状腺结节消融的首次人体临床耐久性研究中取得了积极数据。该研究旨在评估该技术在治疗良性甲状腺结节方面的长期效果与安全性。\n研究结果显示，Npulse™ Vybrance™系统在消融良性甲状腺结节方面展现出显著的持久性，为患者提供了一种潜在的非侵入性治疗选择。这一进展标志着公司在医疗技术领域的创新突破，...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLSE","symbol_name":"Pulse Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1199241533","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199241533","pubTimestamp":1773054139,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Pulse Biosciences公司近日宣布，其Npulse™ Vybrance™系统在针对良性甲状腺结节消融的首次人体临床耐久性研究中取得了积极数据。该研究旨在评估该技术在治疗良性甲状腺结节方面的长期效果与安全性。\n研究结果显示，Npulse™ Vybrance™系统在消融良性甲状腺结节方面展现出显著的持久性，为患者提供了一种潜在的非侵入性治疗选择。这一进展标志着公司在医疗技术领域的创新突破，有望为甲状腺疾病治疗带来新的解决方案。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PLSE":"Pulse Biosciences, Inc.","BK4082":"医疗保健设备"},"translate_title":"Pulse Biosciences Announces Npulse ™ Vybrance ™ Persistence data of benign thyroid nodule ablation in the systematic first human clinical trial","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLSE":1},"content_text":"Pulse Biosciences公司近日宣布，其Npulse™ Vybrance™系统在针对良性甲状腺结节消融的首次人体临床耐久性研究中取得了积极数据。该研究旨在评估该技术在治疗良性甲状腺结节方面的长期效果与安全性。\n研究结果显示，Npulse™ Vybrance™系统在消融良性甲状腺结节方面展现出显著的持久性，为患者提供了一种潜在的非侵入性治疗选择。这一进展标志着公司在医疗技术领域的创新突破，有望为甲状腺疾病治疗带来新的解决方案。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199241533","isCrawlerRequest":true}